Literature DB >> 2690639

The cancer question: an overview of recent epidemiologic and retrospective data.

B E Henderson1.   

Abstract

Unopposed estrogen stimulates mitotic activity in endometrial and breast tissue. Numerous case-control studies have evaluated the relationship between estrogen use and the risk of endometrial and breast cancers. In general, exogenous, unopposed estrogen use increases the risk of endometrial cancer by tenfold and of breast cancer by twofold after long-term use of high doses. Estrogen's positive effects on osteoporosis and coronary heart disease must be considered when evaluating the potential risks associated with its use in postmenopausal women.

Entities:  

Mesh:

Year:  1989        PMID: 2690639     DOI: 10.1016/s0002-9378(89)80007-9

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

Review 1.  The menopause and hormone replacement therapy.

Authors:  K T Khaw
Journal:  Postgrad Med J       Date:  1992-08       Impact factor: 2.401

2.  Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.

Authors:  Yakir Segev; Barry Rosen; Jan Lubinski; Jacek Gronwald; Henry T Lynch; Pal Moller; Charmaine Kim-Sing; Parviz Ghadirian; Beth Karlan; Charis Eng; Dawna Gilchrist; Susan L Neuhausen; Andrea Eisen; Eitan Friedman; David Euhus; Sun Ping; Steven A Narod
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

3.  Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States).

Authors:  P K Green; N S Weiss; B McKnight; L F Voigt; S A Beresford
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506

Review 4.  The adverse effects of hormone replacement therapy.

Authors:  A Tavani; C La Vecchia
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

5.  Hormone replacement therapy: a survey of Ontario physicians' prescribing practices.

Authors:  L Elinson; M M Cohen; T Elmslie
Journal:  CMAJ       Date:  1999-09-21       Impact factor: 8.262

6.  Dietary quercetin inhibits bone loss without effect on the uterus in ovariectomized mice.

Authors:  Mitsuyoshi Tsuji; Hironori Yamamoto; Tadatoshi Sato; Yoko Mizuha; Yoshichika Kawai; Yutaka Taketani; Shigeaki Kato; Junji Terao; Takahiro Inakuma; Eiji Takeda
Journal:  J Bone Miner Metab       Date:  2009-06-04       Impact factor: 2.626

7.  Project for the National Program of Early Diagnosis of Endometrial Cancer Part I.

Authors:  R E Bohîlțea; V Ancăr; M M Cirstoiu; V Rădoi; L C Bohîlțea; F Furtunescu
Journal:  J Med Life       Date:  2015 Jul-Sep

Review 8.  Endometrial hyperplasia as a risk factor of endometrial cancer.

Authors:  Lisa K Nees; Sabine Heublein; Sahra Steinmacher; Ingolf Juhasz-Böss; Sara Brucker; Clemens B Tempfer; Markus Wallwiener
Journal:  Arch Gynecol Obstet       Date:  2022-01-10       Impact factor: 2.493

9.  Hormone replacement treatment and breast cancer risk: a cooperative Italian study.

Authors:  C La Vecchia; E Negri; S Franceschi; A Favero; O Nanni; R Filiberti; E Conti; M Montella; A Veronesi; M Ferraroni
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.